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Mycobacterium bovis BCG recA deletion mutant shows
increased susceptibility to DNA-damaging agents but wild-type
survival in a mouse infection model
Abstract
Pathogenic microorganisms possess antioxidant defense mechanisms for protection from reactive
oxygen metabolites which are generated during the respiratory burst of phagocytic cells. These defense
mechanisms include enzymes such as catalase, which detoxifies reactive oxygen species, and DNA
repair systems, which repair damage resulting from oxidative stress. To (i) determine the relative
importance of the DNA repair system when oxidative stress is encountered by the Mycobacterium
tuberculosis complex during infection of the host and to (ii) provide improved mycobacterial hosts as
live carriers to express foreign antigens, the recA locus was inactivated by allelic exchange in
Mycobacterium bovis BCG. The recA mutants are sensitive to DNA-damaging agents and show
increased susceptibility to metronidazole, the first lead compound active against the dormant M.
tuberculosis complex. Surprisingly, the recA genotype does not affect the in vitro dormancy response,
nor does the defect in the DNA repair system lead to attenuation as determined in a mouse infection
model. The recA mutants will be a valuable tool for further development of BCG as an antigen delivery
system to express foreign antigens and as a source of a genetically stable vaccine against tuberculosis.
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Pathogenic microorganisms possess antioxidant defense mechanisms for protection from reactive oxygen
metabolites which are generated during the respiratory burst of phagocytic cells. These defense mechanisms
include enzymes such as catalase, which detoxifies reactive oxygen species, and DNA repair systems, which
repair damage resulting from oxidative stress. To (i) determine the relative importance of the DNA repair
system when oxidative stress is encountered by the Mycobacterium tuberculosis complex during infection of the
host and to (ii) provide improved mycobacterial hosts as live carriers to express foreign antigens, the recA locus
was inactivated by allelic exchange in Mycobacterium bovis BCG. The recA mutants are sensitive to DNA-
damaging agents and show increased susceptibility to metronidazole, the first lead compound active against
the dormant M. tuberculosis complex. Surprisingly, the recA genotype does not affect the in vitro dormancy
response, nor does the defect in the DNA repair system lead to attenuation as determined in a mouse infection
model. The recA mutants will be a valuable tool for further development of BCG as an antigen delivery system
to express foreign antigens and as a source of a genetically stable vaccine against tuberculosis.
Mycobacterium bovis BCG is a live vaccine against tubercu-
losis that has been administered to more than one billion
people worldwide (6). In addition, BCG is used as a nonspe-
cific immunotherapeutic agent in cancer treatment (38, 41).
Although BCG shows a great deal of geographic variability in
its ability to protect against lung tuberculosis (17), in most
trials, BCG revealed significant protection against early child-
hood tuberculosis and disseminated manifestations of the dis-
ease (6). M. bovis BCG has been suggested as an ideal delivery
system for expression of foreign antigens due to the long per-
sistence of BCG in the immunized host (1, 21, 23, 33, 48, 58).
Despite its widespread use BCG is known to cause severe
infections in immunocompromised individuals (24, 45, 46, 52),
indicating that this organism is endowed with residual viru-
lence properties which may be manifested in the absence of an
effective immune response. It is thought that the ability of
BCG to survive for prolonged periods without causing progres-
sive infection in immunocompetent individuals is an important
component of its protective properties (2).
BCG is known to have undergone significant genetic rear-
rangements, and recent evidence suggests that major recom-
binational events resulting in duplication of large segments of
the chromosome have occurred and are still occurring (3, 16).
Thus, if BCG is to be retained as a vaccine in its own right,
developed as a carrier for generating novel vaccines and still
used as an immunotherapeutic agent, it is essential that a more
genetically stable strain be developed.
Phagocytic cells are able to generate superoxide, hydrogen
peroxide, and other reactive oxygen metabolites which are
capable of damaging microbial DNA, proteins, and mem-
branes (22). Microorganisms possess multiple defenses against
oxidative stress including enzymes such as catalase and DNA
repair systems, which repair damage resulting from oxidative
stress (47). The enzyme catalase catalyzes the decomposition
of toxic hydrogen peroxide to water and oxygen; a correlation
between catalase activity and virulence has been observed for
the Mycobacterium tuberculosis complex (7, 28).
RecA is the regulator of the error-prone DNA repair mech-
anism (SOS response) and a key element of homologous re-
combination (53). The RecA of the M. tuberculosis complex
has an unusual structure, in that it contains a protein-splicing
element, termed intein (10). Difficulties in achieving homolo-
gous recombination in the M. tuberculosis complex have, at
least partially, been attributed to this unusual structure (34).
However, recent data suggest that the M. tuberculosis RecA
intein does not interfere with RecA function (18, 39). DNA
repair mechanisms in general and RecA function in particular
have been shown to be essential for the survival of intracellular
pathogens by repairing DNA damage resulting from oxidative
stress, e.g., in Salmonella enterica serovar Typhimurium (5).
In general, live vaccine strains should possess a RecA2 phe-
notype. (i) Mutant recA strains are genetically more stable than
their recA1 counterparts, reducing concerns about major ge-
netic changes resulting in an altered phenotype (25). (ii) RecA
acts as an inducible positive regulator of interspecies gene
exchange in bacteria (31, 32); a mutant recA allele averts re-
version of virulence attenuation by interspecies gene transfer
(35). (iii) Mutant recA strains are more sensitive to UV irra-
diation and other DNA-damaging agents and thus show re-
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duced persistence in the environment (35). (iv) Expression of
foreign antigens is more stable in a mutant recA background
(43). However, if the lack of a functional RecA results in a
reduced ability to survive in the host, the immunogenicity of,
for example, BCG could be compromised.
To generate M. bovis BCG recA knockout mutants, we
wanted to adapt a technique previously established successfully
for Mycobacterium smegmatis (44). This technique is based on
the dominant-negative selectable marker rpsL1, which confers
streptomycin sensitivity to a streptomycin-resistant host, allow-
ing the isolation of allelic replacement mutants from single-
crossover recombinants. The successful adoption of this strat-
egy would complement other techniques to generate targeted
mutants in the M. tuberculosis complex which make use of a
combined counterselection provided by sacB and a thermosen-
sitive origin of plasmid replication (42). Here we describe the
generation of an M. bovis BCG recA knockout mutant by use of
rpsL as a counterselectable marker and report on the charac-
terization of the mutant with respect to DNA repair, in vitro
induced dormancy, and survival in vivo.
MATERIALS AND METHODS
DNA manipulations and isolation of plasmids. Standard techniques were used
for DNA manipulation. All initial cloning procedures were performed with E.
coli XL1-Blue MRF. Plasmids were prepared with a Qiagen plasmid preparation
kit according to the manufacturer’s recommendations. Plasmid DNA was dis-
solved in Tris-EDTA buffer in concentrations of 500 to 1,000 ng/ml.
Generation of suicide vectors. For the generation of suicide vector
precA::aph-rpsL, the following cloning steps were performed. A 5.2-kb ApaI
fragment from plasmid pEJ126 (10) containing M. tuberculosis recA was sub-
cloned into the PstI site of plasmid pBluescript KSII(2) (Stratagene), resulting
in plasmid pBluescript-recA. From this vector, a 1.3-kbp internal PstI fragment
was replaced by a 1.3-kbp aph cassette isolated as a PstI fragment from plasmid
pUC4K (Pharmacia), resulting in plasmid precA::aph. A fragment comprising
the inactivated recA was removed by digestion with EcoRV and SpeI and cloned
into ptrpA-1-rpsL previously digested with SacI, blunt ended, and subsequently
digested with SpeI (44), resulting in suicide vector precA::aph-rpsL. The cloning
procedures were confirmed by DNA sequencing.
Cultivation of mycobacteria. When cultivated on solid medium, M. bovis BCG
was grown on Middlebrook 7H10 agar supplemented with oleic acid-albumin-
dextrose (OADC) (Difco) for 3 weeks at 37°C. Tween 80 was added to liquid
broth 7H9-OADC to avoid clumping; incubation was performed in a roller bottle
for 10 to 20 days. Antibiotics were added to the following concentrations: kana-
mycin, 25 mg/ml; streptomycin, 25 mg/ml.
Southern blot analyses. For Southern blot analyses, 200 ng of genomic DNA
was digested with an appropriate restriction enzyme, separated on an agarose
gel, and treated according to standard protocols. DNA was transferred to a
Hybond-N membrane (Amersham) and cross-linked by UV irradiation. DNA
was hybridized to a recA probe (a 1.6-kbp ApaI-PstI fragment from pBluescript-
recA) labeled with digoxigenin according to the manufacturer’s instructions
(Boehringer GmbH, Mannheim, Germany), washed under stringent conditions,
and developed with an antibody directed against digoxigenin coupled with horse-
radish peroxidase.
Western blot analyses. M. bovis BCG strains were grown in 100 ml of Dubos
broth and induced with ofloxacin (1 mg/ml) for 24 h, and cell extracts were
prepared as described previously (39). Cell extracts corresponding to 30 mg of
protein were separated by sodium dodecyl sulfate-polyacrylamide electrophore-
sis through a 10% polyacrylamide gel, and the proteins were electroblotted onto
a polyvinylidene difluoride membrane (Immobilon-P; Millipore). The membrane
was blocked with 10% nonfat milk in TTBS (20 mM Tris [pH 7.5)], 0.5 M NaCl
buffer containing 0.1% Tween 20) and incubated with a 1:1,000 dilution of a
mouse antiserum raised against the purified M. tuberculosis RecA protein. A
mouse antibody conjugated to horseradish peroxidase (Dako) was used as sec-
ondary antibody. After being washed with TTBS, the blot was developed with
diaminobenzidine reagent solution as described previously (11).
Generation of M. bovis BCG SMR1. To generate streptomycin-resistant mu-
tants, M. bovis BCG (strain Pasteur) was spread on 7H10-OADC agar containing
streptomycin (20 mg/ml). After 4 weeks of incubation, single colonies were
picked. The genotypes of the streptomycin-resistant strains were determined by
PCR-mediated amplification of rrs and rpsL. The sequencing of rrs and rpsL PCR
products revealed a single A 3 G transition in rpsL codon 88 conferring an
amino acid change from lysine to arginine.
Transformation of M. bovis BCG SMR1. M. bovis BCG SMR1 was grown in a
2-liter roller bottle containing 400 ml of 7H9-OADC–Tween until an optical
density (OD) of 0.6 was achieved. One day before harvesting the cells, glycine
was added to a final concentration of 1.5% (vol/vol), and cells were incubated for
an additional 24 h. All the following steps were performed at room temperature.
Cells were harvested by centrifugation, washed several times with 10% glycerol,
and finally resuspended in a volume of 5 ml. For electroporation, 400 ml of
competent cells was mixed with 1 mg of supercoiled plasmid DNA and electro-
porated (Gene pulser II; Bio-Rad) with the following settings: 2.5 kV, 1,000
ohms, 25 mF. After electroporation cells were resuspended in 4 ml of 7H9-
OADC–Tween and incubated for 20 h with vigorous shaking at 37°C. Following
incubation, appropriate dilutions were plated on selective agar. Single colonies
were picked, restreaked, and grown in liquid broth.
Transformants which had undergone a homologous single crossover were
grown in liquid broth until an optical density of approximately 0.5 was achieved.
Afterwards, appropriate dilutions were spread on plates containing either kana-
mycin or kanamycin plus streptomycin. After 4 weeks of incubation, the efficiency
of counterselection was determined by dividing the number of colonies obtained
on plates containing kanamycin plus streptomycin by the number of colonies
obtained on kanamycin.
EMS and MMS assay. 7H9-OADC medium containing ethylmethane sulfonic
ethyl ester (EMS) or ethylmethane sulfonic methyl ester (MMS) was inoculated
with a 1/50 volume of a freshly grown culture (OD, 0.5). After 6 days of incu-
bation, the OD was determined. 7H9-OADC medium without alkylating chem-
icals served as a control.
UV irradiation assay. For the UV irradiation assay, 100-ml aliquots of a freshly
grown culture (OD at 600 nm [OD600] 5 0.1) were placed in an inverted lid of
a 24-well culture plate and put under a standard germicidal UV lamp (distance,
20 cm). Cells were irradiated for different time periods, and samples were
removed and plated. Mean values and standard deviations from three indepen-
dent experiments are shown. Appropriate dilutions of each culture were plated
out in duplicate.
In vitro induced dormancy. Experiments were performed as described previ-
ously using an in vitro dormancy model (29). Briefly, screw-cap test tubes (20 by
125 mm) with a total fluid capacity of 25.5 ml were used. An early-log-phase
culture was diluted to an OD600 of 0.005 in a total volume of 17 ml of Dubos
broth (Difco). Solid caps with latex liners were tightly screwed down (limited
oxygen supply), and the cultures were gently stirred at 170 rpm for 20 days.
Self-generated oxygen depletion was monitored via the decolorization of the
oxygen indicator dye methylene blue. The growth of cultures was monitored by
determining OD600; viable counts were determined by plating appropriate dilu-
tions on Dubos oleic acid-albumin-agar (Difco). In some cases, metronidazole
was added at a concentration of 10 mg/ml. Mean values and standard deviations
were determined from three independent experiments. Each experiment was
carried out with duplicate cultures. Appropriate dilutions of each culture were
plated out in triplicate.
Infections. BALB/c and nude mice (6 to 8 weeks old) were obtained from the
breeding facility at the National Institute for Medical Research (Mill Hill,
United Kingdom). M. bovis BCG strains were grown in Dubos broth. Logarith-
mically growing cultures were diluted in saline to an OD of 0.8; 0.2 ml (approx-
imately 106 CFU) was injected into the tail vein. Mice were sacrificed according
to ethical guidelines at various times (three mice per BCG strain for each time
point), and the spleens and lungs were removed, weighed, and homogenized. The
suspensions were serially diluted in saline and then plated on 7H10 agar sup-
plemented with OADC. The plates were incubated for 3 weeks. The results were
calculated and expressed as CFU per organ.
RESULTS
Generation of M. bovis BCG recA. Strain M. bovis BCG
SMR1 (for a list of strains and plasmids, see Table 1) is a
streptomycin-resistant derivative of M. bovis BCG; this strain
has a mutation in rpsL codon 88 (Lys 3 Arg), a mutation
known to confer a streptomycin-resistant phenotype.
For generation of recA knockout mutants, M. bovis BCG
SMR1 was transformed with suicide vector precA::aph-rpsL.
This vector carries an M. tuberculosis recA fragment; part of the
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coding region and part of the intein coding region of this
fragment have been replaced by a kanamycin resistance cas-
sette. The wild-type rpsL flanking the inactivated target gene
facilitates isolation of allelic replacement mutants (44). Trans-
formants were selected on medium containing kanamycin (ef-
ficiency in the range of 10 to 50 transformants per mg of
plasmid DNA compared to 2 3 104 transformants per mg of
plasmid DNA when using plasmid pMV361 as a control).
Transformants obtained with plasmid precA::aph-rpsL were
chosen at random for further investigations.
Genetic analysis of transformants and counterselection.
Nine of 11 kanamycin-resistant (KanR) clones investigated
contained the aph cassette, indicating that these colonies arose
from transformation with the suicide vector rather than repre-
senting spontaneous KanR mutants (data not shown).
Genomic DNA was isolated and investigated by Southern blot
analyses using a recA fragment as the probe (Fig. 1). Two of the
nine transformants revealed a pattern indicative of a 59 single
crossover at the recA locus (a 2.6-kbp fragment and a 4.9-kbp
fragment; the wild type shows a 2-kbp fragment) and were
subjected to counterselection on medium containing kanamy-
cin plus streptomycin. Transformants resistant to kanamycin
plus streptomycin (frequency, 1024 to 1025) were screened by
PCR for the absence of the deleted recA intein coding se-
quence (7 of 40 transformants were investigated; data not
shown). recA deletion was confirmed by Southern blot analy-
ses. Following digestion with SmaI the kanamycin- and strep-
tomycin-resistant transformants revealed a single 2.6-kbp frag-
ment (Fig. 1), indicating a second crossover event, resulting in
loss of the functional recA copy. For further investigations, one
of the recA mutants was chosen.
Western blot analyses. Western blot analyses using an anti-
serum raised against M. tuberculosis RecA was performed with
the parental strain, a single-crossover transformant, and the
corresponding knockout mutant (Fig. 2). A single band with a
molecular mass of approximately 40 kDa corresponding to the
mature, spliced form of M. tuberculosis RecA was observed in
extracts of both the parental strain and the single-crossover
transformant but not in the recA mutant, indicating the ab-
TABLE 1. Strains and vectors used
Strain or plasmid Source or reference
Strains
E. coli XL1-Blue MRF .................................................Stratagene
M. bovis BCG strain Pasteur........................................ATCC 35734
M. bovis BCG SMR1.....................................................This study
M. bovis BCG recA1/recA::aph ....................................This study
M. bovis BCG recA::aph................................................This study
Plasmids
pMV361 ..........................................................................48
pEJ126.............................................................................10
pUC4K ............................................................................Pharmacia
pBluescript KSII(2) ......................................................Stratagene
ptrpA-1-rpsL...................................................................44
pBluescript-recA ............................................................This study
pBluescript-recA::aph....................................................This study
precA::aph-rpsL .............................................................This study
FIG. 1. (A) Southern blot analysis of the recA locus. Lane 1, parental M. bovis BCG; lane 2, single-crossover transformant obtained by
transformation with plasmid precA::aph-rpsL; lanes 3 to 5, recA (recA::aph) knockout mutants obtained after counterselection of a single-crossover
transformant on medium containing kanamycin plus streptomycin. Approximately 200 ng of genomic DNA was digested with SmaI and hybridized
to a recA probe. (B) Schematic drawing of the BCG recA locus: the wild-type locus is shown along with the vector used for inactivation, a 59
single-crossover transformant, and a knockout mutant. S, SmaI recognition site.
3564 SANDER ET AL. INFECT. IMMUN.
 at UNIVERSITATSSPITAL on M
arch 27, 2009 
iai.asm
.org
D
ow
nloaded from
 
sence of the RecA protein and thus confirming the data ob-
tained by Southern blot analysis. A faint band with a mass of
approximately 20 kDa possibly corresponding to a truncated
N-terminal RecA fragment was detected in recA single-cross-
over transformants and in the recA knockout mutant.
In vitro characterization of M. bovis BCG recA. (i) M. bovis
BCG recA mutant strains are sensitive to alkylating agents.
One of the most noticeable phenotypes of recA mutant strains
is their increased sensitivity to DNA-damaging agents (26). To
investigate the physiological effects of recA inactivation, several
tests with different DNA-damaging agents were performed.
The ability of recA1 and recA mutant strains to grow in the
presence of EMS or MMS was determined in liquid broth
(Table 2).
The presence of 0.05% EMS only slightly inhibited growth
of the recA1 strain. In contrast, growth of the recA mutant
strain was reduced 10-fold compared to that of the control.
Similar results were obtained with MMS. At a concentration of
0.006% MMS growth of the recA1 strain was not significantly
affected, whereas growth of the recA mutant strain was inhib-
ited by approximately 90%. In the absence of DNA-alkylating
agents the growth rates of the recA1 and the recA mutant
strains were indistinguishable. The single-crossover transfor-
mant essentially behaved like the recA1 strain in the presence
of DNA-damaging agents.
(ii) M. bovis BCG recA mutants are sensitive to UV irradi-
ation. Irradiation with UV light is frequently used to compare
the levels of effectiveness of DNA repair mechanisms. Inacti-
vation of recA rendered BCG sensitive to UV irradiation: the
recA strain exhibited a 10,000-fold-decreased viability after 30 s
of irradiation compared with a 25-fold decrease for the recA1
strain (Fig. 3). The survival rate decreased dramatically at
higher irradiation dosages; very few mutant survivors were
detected after 60 s of irradiation (,0.0001%), compared to
about a 0.01% survival rate for the parental strain. These
results support previous observations that, despite the pres-
ence of an intein, M. bovis BCG RecA is functionally expressed
and promotes DNA repair mechanisms in mycobacteria (18, 40).
(iii) In vitro induced dormancy and metronidazole resis-
tance. The obligate aerobe M. tuberculosis complex can enter
an anaerobic dormant state in which it survives for extended
periods of time (54). To determine whether recA is involved in
the dormancy response, we investigated recA1 and recA mu-
tant strains with respect to their abilities to survive in an in
vitro dormancy model (57). Mycobacteria were grown in sealed
and stirred tubes to achieve self-generated oxygen depletion, a
signal which triggers entry into the dormant state. Growth of
the cultures was monitored by measuring the OD; the number
of cells surviving oxygen depletion was determined by plating.
Self-generated oxygen depletion was judged by fading or de-
colorization of the indicator methylene blue.
With respect to OD, recA1 and recA mutant strains behaved
identically (Fig. 4). A plateau was achieved after approximately
8 days. After day 9 and after day 15, respectively, fading and
decolorization of the oxygen indicator methylene blue were
observed in each of the cultures. After incubation for an ad-
ditional 5 days, cultures were harvested and the numbers of
FIG. 2. Western blot analysis of RecA. Lane 1, parental M. bovis
BCG; lane 2, single-crossover transformant; lane 3, recA knockout
mutant. Approximately 30 mg of protein was separated on a polyacryl-
amide gel, transferred to a polyvinylidene difluoride membrane, and
probed with an antibody raised against M. tuberculosis RecA.
TABLE 2. Growtha in the presence of alkylating agents
Medium
OD for strain carrying:
recA1 recA1/recA recA
7H9-OADC 0.687 0.653 0.679
1 EMS 0.374 0.376 0.077
1 MMS 0.577 0.608 0.098
a Growth as determined by OD600 of the parental recA1 strain, a single
crossover transformant (recA1/recA), and a recA mutant in 7H9-OADC medium
either alone or containing EMS (1 EMS; 0.05% [vol/vol]) or MMS (1 MMS;
0.006% [vol/vol]). Logarithmically growing cultures were diluted to an OD of
0.01 and incubated for 6 days.
FIG. 3. Survival after UV irradiation. Parental M. bovis BCG (F),
a recA single-crossover transformant (f), and a recA knockout mutant
() were irradiated with UV light for the indicated times. Following
irradiation, the numbers of viable cells were determined by plating.
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CFU were determined (Fig. 5). The recA genotype did not
affect the number of viable cells after oxygen depletion, indi-
cating that RecA does not affect in vitro induced-dormancy
survival.
Metronidazole is the first lead compound active against dor-
mant M. tuberculosis. Metronidazole does not affect the growth
of aerobically grown cultures but acts exclusively on the anaer-
obically grown M. tuberculosis complex (56). We next investi-
gated the effect of metronidazole on the growth of recA1 and
recA mutant M. bovis BCG in the in vitro dormancy model
described above. Compared to recA1 M. bovis BCG, the recA
mutant showed increased susceptibility to metronidazole, i.e.,
the number of viable cells was reduced about 20-fold by met-
ronidazole for the recA1 strain, but a 100-fold reduction in the
number of viable cells was observed in the recA mutant (Fig. 5).
Survival of the M. bovis BCG recA mutant in mice. DNA
repair mechanisms in general and RecA in particular are im-
portant virulence factors for the survival of intracellular patho-
gens, such as Salmonella (5). Although wild-type M. bovis BCG
does not cause a progressive infection in mice, it does persist in
tissue for a significant period of time. We thus investigated the
effect of recA inactivation on the survival of M. bovis BCG in a
high-dose animal infection model. BALB/c mice were infected
by intravenous injection with M. bovis BCG recA1, the single-
crossover transformant, and the recA mutant strain. After days
1, 28, and 84, organs (spleen and lung) were removed and
homogenized and appropriate dilutions were plated on 7H10
agar. The plates were incubated for 3 weeks, and the numbers
of CFU per organ were calculated. As shown in Fig. 6, the
knockout mutant showed no difference in the course of infec-
tion compared to the wild-type strain, either in the spleens or
in the lungs of infected BALB/c mice. These data indicate that
RecA is not essential for survival in the high-dose mouse in-
fection model.
Athymic mice were inoculated to assess the virulence of the
recA mutant in a more progressive infection model. As shown
in Fig. 7, a comparison of the three strains in athymic mice did
not show significant difference in growth in spleens or lungs.
DISCUSSION
Infections with M. tuberculosis are a major cause of human
morbidity and mortality. Vaccines are the most cost-effective
intervention to prevent disease, and M. bovis BCG is a widely
FIG. 4. Growth under dormancy conditions. Parental M. bovis
BCG (F) and the recA knockout mutant () were grown under dor-
mancy culture conditions. Growth was determined by measuring the
OD. F and D, fading and complete decolorization of the methylene
blue indicator, respectively.
FIG. 5. Survival under dormancy conditions. Survival of parental
M. bovis BCG and the recA knockout mutant under dormancy culture
conditions was investigated by determining the numbers of CFU after
20 days of incubation in the presence or absence of metronidazole
(MTZ; 10 mg/ml).
FIG. 6. Course of infection in BALB/c mice. Parental M. bovis
BCG (F), a recA single-crossover transformant (f), and a recA knock-
out mutant () were injected into the tail vein (approximately 106
CFU/animal). The numbers of bacteria in spleens (A) and lungs (B)
were determined at different time points.
FIG. 7. Course of infection in nude mice. Parental M. bovis BCG
(F), a recA single-crossover transformant (f), and a recA knockout
mutant () were injected into the tail vein (approximately 106 CFU/
animal). The numbers of bacteria in spleens (A) and lungs (B) were
determined at different time points.
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used vaccine; it can be given as a single dose at birth and
confers long-lasting immunity. M. bovis BCG not only is used
as vaccine against tuberculosis but also offers great potential
for innovative approaches for development of polyvalent vac-
cines (1, 33, 48, 58). Genetic stability and in vivo persistence
are of special importance for the use of live vaccines; a mutant
BCG which is rapidly eliminated is unlikely to be an effective
vaccine (2).
RecA is a multifunctional and ubiquitous protein involved
both in general recombination and in DNA repair. Thus,
RecA-mediated DNA repair mechanisms have been shown to
be essential for intracellular survival and persistence (5), while
simultaneously RecA-dependent recombination mediates ge-
netic rearrangements resulting in increased genetic instability
(25). As an inducer of the SOS response RecA regulates at
least 20 genes, most of which are usually suppressed by LexA
(36); mycobacteria possess the key elements of a functional
SOS system (13, 37).
Investigations of M. tuberculosis RecA so far have been
performed in vitro, with Escherichia coli and M. smegmatis (10,
11, 12, 18, 27, 40, 51). These investigations demonstrated that
the mature RecA is able to promote DNA repair mechanisms
and homologous recombination (18, 40). However, as no iso-
genic M. tuberculosis complex mutants were available, the pos-
sibility that a homologous gene, e.g., radA (Rv3585) (8), could
compensate for RecA function could not be excluded. The
results presented here show that BCG recA mutants are sen-
sitive to DNA-damaging agents (DNA alkylation and UV ir-
radiation) and thus have an in vitro phenotype similar to those
of recA mutants of other species (36). These investigations
suggest that M. bovis BCG has a nonredundant recA gene,
which is essential to promote DNA repair mechanisms.
M. bovis BCG and M. tuberculosis are able to enter a dor-
mant state (29). This response is triggered by slow self-gener-
ated depletion of oxygen (54). Entry into the dormant state is
an adaptive process, as sudden oxygen depletion results in cell
death (55). Experiments in an in vitro dormancy model were
performed to investigate whether RecA is involved in dor-
mancy survival. As the numbers of viable bacterial cells after
oxygen depletion were essentially identical for the recA1 and
recA mutant strains, RecA does not appear to play an essential
role in entry, survival, or exit from the dormant state.
Originally developed as an antiparasitic agent, metronida-
zole has been recognized as an effective drug for treatment of
infections with anaerobic bacteria. Metronidazole is also active
against M. tuberculosis and M. bovis BCG when grown under
anaerobic conditions (29, 56). Our investigations in the in vitro
dormancy model demonstrated that M. bovis BCG recA knock-
out mutants show increased susceptibility to metronidazole.
These results support previous findings that metronidazole acts
by damaging DNA after reduction to form a toxic metabolite
(15).
Numerous reports have demonstrated that recA represents
an important virulence factor: RecA is involved in stress sur-
vival (14), mediates aerotolerance in microaerophilic bacteria
(9), induces production of colicins, pyocins (36), and extracel-
lular degradative enzymes (30), and mediates amplification of
toxin genes (19). Most notably, Salmonella recA mutant strains
are highly attenuated, both in cultured macrophage cells (4)
and in a mouse infection model (5). This effect has been at-
tributed to the DNA-damaging effect of the oxidative burst and
the reduced ability of the mutants to perform DNA repair (47).
However, a recA mutation does not necessarily affect bacterial
virulence, as demonstrated, e.g., for Campylobacter jejuni (20),
Corynebacterium pseudotuberculosis (43), Brucella abortus (50),
and some Vibrio cholerae strains (49). It was thus of interest to
investigate the contribution of RecA to the survival of M. bovis
BCG in mice. The results indicate that RecA does not con-
tribute to the establishment and maintenance of infection. This
is an important finding since persistence of BCG following
vaccination is thought to be a significant contributory factor to
its immunogenicity; a mutant BCG which is rapidly eliminated
is unlikely to be an effective vaccine.
In analogy to M. tuberculosis (3, 16) differences between
strains of M. bovis BCG can be attributed to RecA-dependent
genetic rearrangements. The BCG recA mutant constructed in
this study is deficient in the major recombination pathway but
is not affected in its in vivo survival. Due to the increased
genetic stability of recA mutants, this strain is of interest as a
tuberculosis vaccine and for further development of M. bovis
BCG as an antigen delivery system for expression of foreign
antigens.
The BCG mutant was generated by adapting an rpsL-based
strategy which has previously been used to generate allelic
exchange mutants in M. smegmatis (44). As transformation
efficiencies are a critical issue, the original strategy has been
modified to a two-step allelic exchange procedure incorporat-
ing successive steps of positive and negative selection. The
procedure described is a valuable alternative to strategies
which use sacB and thermosensitive vectors for the generation
of allelic exchange mutants in mycobacteria (42).
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